Overview
Functional brain mapping allows for the correlation of abnormalities in various cortical networks with a patient’s symptom’s or deficits. For instance, brain-mapping combines neuropsychological testing of cognition with the results from sLORETA or fMRI brain mapping. At NCI, we predominantly use sLORETA analysis which is an electrical neuroimaging technique. This advanced neurodiagnostic procedure allows us to more accurately diagnose and treat a wide variety of cognitive, neurobehavioral and neuropsychiatric disorders. For example, we can map various cortical networks in the brain, such as the attention, executive, language, depression, or the pain network. If abnormalities are detected, we can identify the precise location within the network and determine if these deviations are due to cortical tone, connectivity and/or timing abnormalities. We are able to determine if the finding is abnormal by comparing the brain mapping results to a large age and gender matched normative database. In addition, we use various clinical databases to generate a Probability Index score to assess the probability that the abnormalities are due to central nervous system disorders such as ADHD, Alzheimer’s Disease, Seizures, Traumatic Brain Injury or a Learning Disability.
Currently, the largest normative and clinical databases of brain imaging data have been developed from electrical neuroimaging techniques. These databases continue to be cross validated with multiple other functional brain mapping techniques such as functional MRI. Using source analysis software, brain topography and tomography imaging not only has excellent (time) resolution, but structural location can be computed throughout the cortex including the limbic system. Spatial resolution as precise as a 3 mm are of localization using standardized MRI imaging templates can be visualized. Another advantage, and perhaps this is the most important advantage, electrical neuroimaging can also be used as an intervention.
Interventional Brain Mapping
Neuromodulation treatment applications sucha s transcranial direct current stimulation (tDCS), rapid transcranial magnetic stimulation (rTMS) and EEG Neurofeedback can be used to treat clinically significant brain abnormalities detected on brain mapping. Among these various neuromodulation applications, Neurofeedback currently has the widest range of clinical applications. Although Neurofeedback has been used as a clinical tool since the 1960s, brain mapping neurofeedback using LORETA software is a relatively recent development dating back to approximately 2008. This technology uses advancements made over the past 15 years mapping multiple brain circuits responsible for a plethora of human experiences; from basic functions such as sustaining wakefulness to complex functions such as decision-making.
Clinically, sLORETA Neurofeedback is rapidly growing around the globe as a treatment application to alter brain networks that are not functioning at their optimal levels. In non-clinical populations, brain mapping Neurofeedback is also being used to enhance performance and cognitive functions such as reaction time and decision speed in individuals who are functioning in highly-competitive environments.
For additional information on these and other recently developed diagnostic tests, treatment interventions such as cognitive rehabilitation, behavioral management, psychotherapy, psychopharmacological and nutraceutical treatments, clinical research trials, as well as, peak performance training — please call the NeuroCognitive Institute and schedule a consultation. Neuroimaging, FBMAP and neuromodulation interventions such as neurofeedback are clinical procedures and reimbursed by most 3rd party healthcare insurance carriers. NCI participates in most healthcare plans including Medicare and Mediaid.
One of Many Scientific References on Functional Brain Mapping and Neuromodulation
Functional Brain Mapping and the Endeavor to Understand the Working Brain: Signorelli and Chirchiglia (2013).
Mind Over Chatter: Plastic up-regulation of the fMRI salience network directly after EEG Neurofeedback. Neuroimage, 65, 324-335.
Quantitative Structural MRI for early detection of Alzheimer’s disease: McEvoy and Brewer (2010). Expert Reviews in Neurotherapy. November: 10 (11): 1675-1688.
